MeiraGTx/$MGTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MeiraGTx
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Ticker
$MGTX
Sector
Primary listing
Employees
386
Headquarters
Website
MeiraGTx Metrics
BasicAdvanced
$590M
-
-$2.03
1.30
-
Price and volume
Market cap
$590M
Beta
1.3
52-week high
$8.98
52-week low
$3.94
Average daily volume
324K
Financial strength
Current ratio
0.881
Quick ratio
0.729
Long term debt to equity
2,629.122
Total debt to equity
2,718.547
Interest coverage (TTM)
-12.29%
Profitability
EBITDA (TTM)
-145.318
Gross margin (TTM)
26.56%
Net profit margin (TTM)
-415.39%
Operating margin (TTM)
-416.49%
Revenue per employee (TTM)
$100,000
Management effectiveness
Return on assets (TTM)
-42.42%
Return on equity (TTM)
-379.53%
Valuation
Price to revenue (TTM)
15.005
Price to book
199.22
Price to tangible book (TTM)
265.86
Price to free cash flow (TTM)
-4.247
Free cash flow yield (TTM)
-23.55%
Free cash flow per share (TTM)
-1.726
Growth
Revenue change (TTM)
366.84%
Earnings per share change (TTM)
36.36%
3-year revenue growth (CAGR)
-5.11%
3-year earnings per share growth (CAGR)
-3.69%
What the Analysts think about MeiraGTx
Analyst ratings (Buy, Hold, Sell) for MeiraGTx stock.
Bulls say / Bears say
The strategic partnership with Hologen AI brings $200 million upfront and commits up to $230 million more via a joint venture, fully financing AAV-GAD to commercialization, which significantly de-risks the Parkinson’s program and strengthens the company’s balance sheet (Nasdaq)
In May 2025, the FDA granted RMAT designation to AAV-GAD for Parkinson’s disease, citing positive Phase 2 sham-controlled results that showed significant UPDRS Part 3 improvements, setting the stage for expedited regulatory pathways and potential Priority Review (GlobeNewswire)
As of June 30, 2025, MeiraGTx had $34.4 million in cash and restricted cash, along with $2.3 million in J&J receivables and expected Hologen proceeds, providing funding runway through 2027 and coverage for the $75 million debt maturing in August 2026 (GlobeNewswire)
Cash and cash equivalents dropped 69% year-over-year from $103.7 million as of December 31, 2024 to $32.2 million on June 30, 2025, highlighting significant cash burn and heavy dependence on milestone payments to fund operations through 2027 (GlobeNewswire)
Patient enrollment in the high-dose cohorts of the Phase 2 AQUAx2 trial for AAV2-hAQP1 is ongoing, with completion not expected until Q4 2025, pushing pivotal data readout to late 2026 and delaying any BLA submission or potential revenue (GlobeNewswire)
MeiraGTx posted a net loss of $38.8 million in Q2 2025, demonstrating ongoing unprofitability and the risk of additional dilution if clinical development or regulatory milestones are delayed (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
MeiraGTx Financial Performance
Revenues and expenses
MeiraGTx Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MeiraGTx stock?
MeiraGTx (MGTX) has a market cap of $590M as of September 16, 2025.
What is the P/E ratio for MeiraGTx stock?
The price to earnings (P/E) ratio for MeiraGTx (MGTX) stock is 0 as of September 16, 2025.
Does MeiraGTx stock pay dividends?
No, MeiraGTx (MGTX) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next MeiraGTx dividend payment date?
MeiraGTx (MGTX) stock does not pay dividends to its shareholders.
What is the beta indicator for MeiraGTx?
MeiraGTx (MGTX) has a beta rating of 1.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.